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Abstract
Background: Dissociative seizures (DSs), also called psychogenic non-epileptic seizures, are a distressing and disabling
problem for many patients in neurological settings with high and often unnecessary economic costs. The COgnitive
behavioural therapy versus standardised medical care for adults with Dissociative non-Epileptic Seizures (CODES)
trial is an evaluation of a specifically tailored psychological intervention with the aims of reducing seizure frequency
and severity and improving psychological well-being in adults with DS. The aim of this paper is to report in detail the
quantitative and economic analysis plan for the CODES trial, as agreed by the trial steering committee.
Methods: The CODES trial is a multicentre, pragmatic, parallel group, randomised controlled trial performed to
evaluate the clinical effectiveness and cost-effectiveness of 13 sessions of cognitive behavioural therapy (CBT)
plus standardised medical care (SMC) compared with SMC alone for adult outpatients with DS.
Discussion: The objectives and design of the trial are summarised, and the aims and procedures of the planned analyses
are illustrated. The proposed analysis plan addresses statistical considerations such as maintaining blinding, monitoring
adherence with the protocol, describing aspects of treatment and dealing with missing data. The formal analysis approach
for the primary and secondary outcomes is described, as are the descriptive statistics that will be reported. This
paper provides transparency to the planned inferential analyses for the CODES trial prior to the extraction of outcome
data. It also provides an update to the previously published trial protocol and guidance to those conducting
similar trials.
Trial registration: ISRCTN registry ISRCTN05681227 (registered on 5 March 2014); ClinicalTrials.gov
NCT02325544 (registered on 15 December 2014).
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Background
CODES trial
The COgnitive behavioural therapy versus standardised
medical care for adults with Dissociative non-Epileptic
Seizures (CODES) trial is a multicentre, pragmatic, paral-
lel group, randomised controlled trial (RCT) performed to
evaluate the clinical effectiveness and cost-effectiveness of
13 sessions of cognitive behavioural therapy (CBT) plus
standardised medical care (SMC) compared with SMC
alone in reducing dissociative seizure (DS) frequency and
severity and improving seizure freedom, quality of life,
psychosocial well-being and cost-effectiveness in terms of
health service use in adults with non-epileptic DSs [1].
The protocol paper for the CODES trial has been pub-
lished previously [1]; the aim of this paper is to report in
detail the quantitative and health economic analysis plan
as agreed by the trial steering committee in April 2016.
Dissociative seizures
Approximately 12–20% of patients seen in epilepsy clinics
may be having DSs rather than epileptic seizures [2], and
rates of DS incidence have been estimated at around 4.9/
100,000/year [3]. Although DSs are paroxysmal events
that resemble epileptic seizures or syncopes, they are not
associated with ictal electroencephalographic discharges.
Other common names for DS include psychogenic non-
epileptic seizures and non-epileptic attacks, and they are
found under the umbrella headings of dissociative and
conversion disorders in psychiatric classifications. DS pre-
sents a challenge for clinicians in terms of diagnosis and
management. Patients with DS demonstrate high rates of
psychiatric comorbidities such as anxiety, depression and
post-traumatic stress disorder [4], and it has been shown
that they have a raised risk of mortality unrelated to their
seizures [5]. Patients with DS may go through expensive
or unnecessary interventions; they can sustain injuries
during a seizure; and their quality of life is lower than in
patients with epilepsy [6]. It has been shown that medical
service use and costs can be reduced if a correct diagnosis
is given [7].
Despite limited evidence to date for its effectiveness
[8–12], psychotherapy is viewed as the treatment of
choice for DS [13]; however, the involvement of psy-
chiatrists and psychologists is variable. The National
Institute for Health and Care Excellence [14] and the
Scottish Intercollegiate Guidelines Network [15] have
recognised the need for psychiatric and psychological
input for patients with DS, who would benefit from
the development of neuropsychiatric care pathways
[16] (i.e., bridging the gap between neurology and
psychiatry). However, there is little basis on which to
recommend a particular type of psychotherapy for
this patient group, and care provision in the United
Kingdom remains extremely variable.
The CODES trial will therefore permit evaluation of
the clinical effectiveness and cost-effectiveness of CBT
specifically adapted for patients with DS within a struc-
tured care pathway involving neurology, liaison/neuro-
psychiatry and psychotherapy and should then provide a
model for future services and more rational commis-
sioning of care for this patient group. It will provide a
basis for the wider training of therapists to work with
patients with DS and support the role of psychiatrists in
treating this group of patients, who commonly have
complex mental health care needs.
Research objectives
Primary objective
Our primary objective is to evaluate the effectiveness of
CBT (plus SMC) compared with SMC alone in reducing
monthly DS frequency at 12 months post-randomisation.
Secondary objectives
Our secondary objectives are to evaluate the effective-
ness of the intervention in terms of further secondary
outcomes, specifically to assess the following:
1. Reductions in subjective DS severity and disability,
as well as improvements in seizure freedom,
psychosocial and psychological well-being, and
health-related quality of life following CBT plus
SMC compared with SMC alone at 12 months
post-randomisation
2. A reduction in health service use at 12 months
post-randomisation following CBT plus SMC
compared with SMC alone
3. The cost-effectiveness of CBT plus SMC compared
with SMC alone at 12 months post-randomisation
In addition, we seek to characterise the following:
4. The global clinical improvement shown by patients
as a result of either treatment
5. Participants’ satisfaction with either treatment
Outcome measures
The primary outcome measure is monthly DS frequency
at 12 months post-randomisation, defined as seizure
occurrence over the previous 4 weeks [1]. This will also
be collected at 6 months post-randomisation as an auxil-
iary variable (see explanation below). Seizure frequency
data will be recorded by patients in daily seizure diaries
and will be collected by the research workers every
2 weeks throughout the trial by whichever means
patients find acceptable (diaries, text/phone/online). The
research workers will then enter the data as weekly seiz-
ure counts into the database system (MACRO; InferMed
Ltd, London, UK) set up for this trial by King’s Clinical
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Trials Unit (KCTU) at the Institute of Psychiatry,
Psychology and Neuroscience in London.
Monthly DS frequency will be converted into an inci-
dence rate by the trial statistician. The incidence rate is
defined as the number of seizures (count) divided by the
number of days. The number of days will depend on
how many weekly seizure counts are recorded for each
participant at the follow-up time points (7, 14, 21 or
28 days). If the seizure diary has not been collected for
the relevant 4 weeks at 6 months (weeks 23–26) and
12 months (weeks 49–52) post-randomisation, an allow-
ance of 2 weeks on either side of these time points will
be given to calculate monthly seizure frequency.
An overall self-report estimate of DS frequency in the
preceding 4 weeks will also be requested from partici-
pants at baseline and at the two follow-up time points to
help deal with missing diary data. See the trial protocol
[1] for further details of all outcome measures and as-
sessment timings.
Trial design
The CODES trial is a multicentre, parallel group, super-
iority RCT. It comprises a two-stage screening phase: (1)
an initial assessment is carried out at recruitment, and
(2) a re-assessment is conducted at the psychiatrist visit
approximately 3 months later. Further information on
this eligibility screening can be found in the protocol
publication [1], and an illustration of the screening,
recruitment, randomisation and follow-up process is
provided in Fig. 1.
Once both phases of consent and baseline assessments
are complete, the individuals are randomised to one of the
treatment arms. The procedure is as follows. Upon receipt
of notification that the patient has consented to partici-
pate in the RCT and that the baseline questionnaires have
been completed, the local research worker electronically
submits details of each participant to the KCTU online
randomisation system (www.ctu.co.uk/randomisation).
This includes the participant’s identification number,
study centre, initials and date of birth. The system
generates confirmation emails that can be blinded or
unblinded to treatment allocation. Therefore, relevant
staff will be notified immediately of the treatment
allocation, with or without unblinded details, depend-
ing on their role in the study. Specifically, the
research workers will receive a blinded confirmation
of successful randomisation, and the trial manager
and principal investigator will receive an unblinded
notification. The CBT therapists delivering the man-
ualised CBT will be informed of the details of the
person randomised to that intervention by the trial
manager and will liaise with patients to arrange their
attendance at appointments.
Randomisation and blinding
Randomisation is undertaken using a 1:1 ratio and is
stratified by liaison/neuropsychiatry centre with variable
block sizes within centres to ensure that the distribution
of centres is balanced across the two trial arms. There
are a total of 18 centres that are involved with patient
randomisation.
Blinding is planned for outcome assessors (research
workers) and the trial statistician. Evidence for unblind-
ing of treatment to assessors will be studied to ascertain
whether they can tell to which treatment arm the partic-
ipants are randomly allocated for the trial; at 12 months
or at withdrawal, the assessors will guess the arm to
which they think the participants were allocated. The
trial statistician will then compare whether the propor-
tions who guess CBT in each arm is different.
Sample size
Data are derived from our pilot RCT study (comparing
CBT and SMC on a comparable population), which was
the largest study at the time informed our sample size
calculations [11]. Analysis of seizure outcome in that
study was controlled for pre-randomisation seizure
frequency, and it revealed a large standardised effect size
of Cohen’s d = 0.75 [17] (logarithmic scale) for seizure
frequency reduction following CBT compared with SMC
at the end of CBT treatment (measured at a comparable
time point for the SMC group). Of relevance for the
calculation of the CODES sample size, our earlier study
also yielded a moderate effect size of Cohen’s d = 0.42
(logarithmic scale) 6 months after the end of treatment,
which broadly approximates the 12-month post-
randomisation follow-up point in the CODES trial.
We therefore based our sample size estimation on
this moderate effect size, which we considered to be
clinically meaningful.
We were also able to consider effect sizes for other
non-seizure-related outcomes. We found that in other
studies of CBT-based psychotherapy for functional
symptoms, it is not uncommon to obtain moderate
effect sizes. For example, researchers in a large RCT
studying patients with chronic fatigue syndrome that
permitted a comparison between CBT and standard
medical care reported a standardised effect size of
d > 0.5 at 52 weeks post-randomisation [18]. An RCT
study of a brief guided self-help CBT approach for
patients with a mixture of functional neurological
symptoms (10% of whom had DS) yielded an effect
size of d = 0.48 at 3 months [19]. Thus, we are aiming
to be able to detect an effect size comparable to that
found in other CBT-based interventions with patients
with functionally/medically unexplained symptoms.
An initial calculation suggested that 121 partici-
pants per group were needed to detect an effect size
Robinson et al. Trials  (2017) 18:258 Page 3 of 9
of d = 0.42 with 90% power at the 5% significance
level using a two-sided t test for logarithmic frequen-
cies. However, this number needed to be inflated to
allow for therapist effects within the CBT group.
Therefore, by using an intra-class correlation coeffi-
cient (ICC) of 0.02, which is based on a typical ther-
apist ICC [20], and assuming that around 15
therapists will be delivering CBT, the sample size
increased to 149 participants per arm, which would
achieve 92.6% power (using the cluspower command in
Stata, allowing for clustering in only one trial arm).
As explained further in the Inferential analysis section
below, pre-randomisation seizure frequency will be
recorded for all of the participants and included as a
covariate in the analytical model. This means that the
precision of future intervention effect estimates will
increase, and so, to account for this, we applied a defla-
tion factor of 0.83, which is based on a correlation
Fig. 1 COgnitive behavioural therapy versus standardised medical care for adults with Dissociative non-Epileptic Seizures (CODES) trial Consolidated
Standards of Reporting Trials (CONSORT) diagram. RCT Randomised controlled trial, CBT Cognitive behavioural therapy, SMC Standardised medical care
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between pre-randomisation and follow-up in frequencies
of r = 0.42 [21]. Finally, attrition needed to be accounted
for to re-inflate the sample size. In the pilot RCT, 11% of
patients were lost to follow-up [11], but we allowed for a
more conservative attrition rate of 17% at 12 months.
Therefore, we aim for a final sample size of 149 partici-
pants per arm and a total of 298 participants.
Treatment duration and timing of outcome assessments
CBT therapists who have undergone further specific
training for the CODES trial will deliver 12 sessions of
CBT plus 1 booster session. CBT will take place over
4–5 months along with a further booster session
approximately 9 months after randomisation. All partici-
pants will complete follow-up measures at two time
points: 6 and 12 months post-randomisation. The aim is
for follow-up assessments to be collected up to 4 weeks
before and up to 8 weeks after the two time points, where
outcomes can be considered reasonably constant. If a
large proportion of outcome data is collected outside this
stability window, then sensitivity analysis will be consid-
ered to adjust for the time difference. Participants rando-
mised to SMC alone will be referred for psychotherapy if
they are deemed clinically to require this at the end of the
study and after follow-up is complete, but no further data
will then be collected on these people, and this treatment
course will not form part of the clinical trial.
Auxiliary information
As explained above, the primary outcome is seizure
frequency at 12 months post-randomisation as recorded
in patient seizure diaries. We also collect further reports
of seizure frequency: seizure frequency at 6 months
post-randomisation and patient self-reported number of
seizures in the last 4 weeks. We will use such auxiliary
information to assess the size of measurement error in
our primary outcome and also to predict missing values
in the primary outcome analysis (see below for descrip-
tion of multiple imputation [MI] process). Regarding
measurement precision, Cohen’s kappa statistic and
Spearman’s rank correlation coefficients will be calcu-
lated to assess inter-measurement method reliability and
the strength of any monotonic relationship.
Data analysis plan
Baseline comparability of randomised groups
Baseline descriptions of participants by treatment and
overall will be provided as minimums and maximums,
means and SDs, and medians and quartiles for continu-
ous variables as appropriate. Frequencies and propor-
tions will be presented for categorical variables. No
significance testing will be used to test baseline differ-
ences between the trial arms. All baseline variables will
be reported overall and by trial arm. These will be
grouped into participant demographics and participant
clinical information. The primary and secondary out-
comes will also be summarised overall and by trial arm.
Adherence to allocated treatment
Within the CBT arm, adherence to allocated treatment
will be described using study-specific therapy logs com-
pleted by the CBT therapists. These logs will be used to
record attendance at CBT sessions or reasons for non-
attendance, as well as rate completion of homework
tasks, implementation of activities negotiated in sessions,
and whether DSs experienced in session disrupted ther-
apy. Compliance (adherence) is defined as having
attended at least nine of the sessions of CBT. A sum-
mary of the number of CBT sessions attended and the
number of patients compliant with CBT sessions will be
provided. Compliant versus non-compliant participants
will be compared on baseline variables, and the reasons
for withdrawal from treatment will be summarised.
In addition, CBT sessions will be recorded with partici-
pants’ consent, and a random selection of these audio
recordings will be used to rate therapy integrity to assess
the extent to which therapists adhered to the study-
specific CBT [1]. The number of participants in the
SMC arm who received the active treatment component
(CBT) (i.e., treatment contamination) will be described.
This will be compared against the health service use data
in the economic analysis for consistency.
Loss to follow-up and other missing data
Withdrawal from trial follow-up (attrition rate) will
be reported by intervention group. The proportions
of participants with missing values for each variable
will be summarised in each arm and at each time
point. The reasons for withdrawal from the trial will
be summarised.
The baseline characteristics of those missing 12-month
follow-up data will be compared with those with complete
follow-up. The relationship between baseline characteris-
tics and missing data will also be investigated graphically.
Imputation by chained equations (ICE), a form of MI, will
be used in the formal analysis to deal with missingness,
and predictive baseline characteristics will be included in
this process.
The relationship between drop-out from therapy and
loss to follow-up will also be described. This will be
performed by an independent statistician to maintain
blinding of the trial statistician. Binary variables will be
constructed for completion of at least nine CBT sessions
(“compliant”) and for drop-out at 12 months. The rela-
tionship between these two post-randomisation variables
within the CBT arm will be assessed by using a chi-
square test and will inform the decision whether to
include this ‘compliance’ variable in the ICE step,
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which is explained further in the ‘Inferential analysis’
section below.
Adverse event reporting
Adverse events, adverse reactions, serious adverse events
and serious adverse reactions will be summarised by trial
arm and overall.
Descriptive statistics for outcome measures
Each of the primary and secondary outcome measures
as listed in the protocol [1] will be described by treat-
ment group and time point. Means and SDs or medians
and IQRs will be used for continuous variables, where
relevant. We will check whether continuous outcomes
can be assumed to be normally distributed using visual
diagnostics, such as residual plots. Histograms and
goodness-of-fit tests will be used to assess whether the
count variables have a Poisson distribution (i.e., whether
the variances equal the means or if there is evidence of
over-dispersion). Frequencies and proportions will be
used to describe categorical variables.
Inferential analysis
Aims of formal inferences
An intention-to-treat approach will be employed to esti-
mate effectiveness. The formal statistical analyses will
estimate the differences in relevant summaries (means,
incidence rates) between patients randomised to CBT
plus SMC and SMC alone at the various post-treatment
observation time points. Group difference estimates and
associated 95% CIs will be reported. The significance
level will be 5% (two-sided) for the primary outcome.
Missing post-randomisation assessments will be dealt
with by using the ICE approach for MI. Provided that
predictors of missingness are included in the ICE step,
the analysis should remain valid in the presence of
missing data under the missing at random (MAR)
assumption.
The trial statistician will remain blinded until the main
analyses have been completed. Any analyses that cannot
be performed blinded (e.g., modelling therapist effects in
the CBT arm) will be done at the end of the analysis to
preserve blinding for as long as possible. Sensitivity
analyses will be used to assess the robustness of conclu-
sions to non-ignorable missing outcome data and to
departures from randomised treatment.
Analysis of the primary outcome
The analysis population will include all patients who are
randomised. The primary outcome is monthly seizure
frequency at 12 months post-randomisation, defined as
seizure occurrence over the previous 4 weeks. For the
purpose of the primary outcome analysis, this will be
taken as measured by the seizure diaries. Other seizure
variables will be included in the imputation step, as
explained below.
Seizure frequency will be captured by a seizure count
and an exposure period. An individual’s incidence rate is
then defined by the number of seizures divided by num-
ber of days (7, 14, 21 or 28 days), as explained above.
The frequency outcome will be modelled using general-
ised linear mixed models (GLMMs) for Poisson data.
The count outcome at 12 months will constitute the
dependent variable, and an offset will be used to
acknowledge any variability in exposure periods. A Pois-
son model expresses the effect of the intervention in the
form of an incidence rate ratio contrasting the expected
number of seizures under CBT plus SMC with the
expected number under SMC alone.
The explanatory variables will be seizure frequency at
baseline, randomisation stratifier (liaison/neuropsych-
iatry clinics) and trial arm. The model also contains
participant-varying random intercepts to account for any
over-dispersion. Potential clustering will be assessed in
the model by considering including doctor-varying
random intercepts to account for effects of the doctor
delivering SMC and therapist-varying intercepts in the
CBT arm to account for therapist effects. Poisson model
assumption checks are described below.
The model will be estimated using MI (specifically
ICE) and will allow for missing outcome data under the
MAR assumption. The analysis is valid provided this
assumption holds; this means that the observed variables
driving missingness have been included in the ICE step.
Predictors of missingness (i.e., baseline characteristics
and compliance with treatment in the CBT arm) will be
included in the ICE step; this is aimed at ensuring that
our MAR assumption is realistic.
In addition, all of the explanatory variables used in the
analytical model will be included in the ICE step to
ensure that the imputation model is at least as general
as the analytical model. Importantly, the ICE step will
also contain seizure frequency at 6 months and auxiliary
variables for seizure outcomes to make a more realistic
MAR assumption and gain precision. The effect of
departures from this MAR assumption on results will be
assessed using sensitivity analyses [22].
Analysis of secondary outcomes
Secondary patient outcomes relating to DS severity and
disability, health-related quality of life, well-being, global
clinical improvement and satisfaction with treatment will
be analysed using similar GLMMs. For example, con-
tinuous variables such as quality of life will be modelled
using regression with random effects, accounting for
doctor or therapist clustering if necessary. Transforma-
tions will be investigated for secondary outcomes that
are unlikely to be normally distributed. Binary variables
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such as seizure freedom in last 3 months (yes/no) will be
analysed using logistic regression with random effects.
Similarly to the primary outcome analysis, secondary
outcome measures at 6 months post-randomisation will
be used as auxiliary variables in the imputation model to
account for missingness. Secondary outcomes relating to
the economic objectives are explained below in the
health economic plan.
Statistical considerations
Missing items in scales and subscales
The number (percent) with complete data will be
reported. The ideal approach would be to use missing
value guidance provided for scales. Where this is not
available, scales will be prorated for an individual if 20%
of items or less are missing. For example, in a scale with
ten items, prorating will be applied to individuals with
one or two items missing. The average value for the
eight or nine complete items will be calculated for that
individual and used to replace the missing values. The
scale score will be calculated on the basis of complete
values and these replacements.
Missing baseline data
We do not anticipate missing values in pre-randomisation
variables. However, if we encounter missing baseline
values, then we can also use the MI process as explained
above, or they can be singly imputed according to the
method of White and Thompson [23].
Method for handling multiple comparisons
There is only a single primary outcome, and no formal
adjustment of p values for multiple testing will be ap-
plied. However, care should be taken when interpreting
the numerous secondary outcomes.
Method for handling non-compliance
In addition to the primary intention-to-treat analysis,
the effect of actually receiving treatment as defined in
the protocol will also be estimated. If non-compliance
with treatment is high in the CBT arm, a complier aver-
age causal effect (CACE) analysis will be considered.
CACE analysis examines the effect of CBT among com-
pliers. Complier status is observable only in the CBT
arm. Instrumental variable methods using randomisation
as an instrument for CBT receipt will enable estimation
of CACE without incurring bias [24].
Model assumption checks
To assess the adequacy of the Poisson regression model
for the primary outcome, we will first look at the basic
descriptive statistics for the count data. A Poisson model
assumes that each seizure is independent of each other
and that the count mean and variance are similar;
therefore, if they are very different, this may be an issue
of over-dispersion. A goodness-of-fit chi-square test will
be performed to assess the model fit; if the test is not
statistically significant, then the Poisson model fits well,
and distributional assumptions are met. However, if the
Poisson assumptions are violated, then a negative bino-
mial model may be considered more appropriate
because an extra parameter can model the over-
dispersion. For the secondary outcomes, regression resid-
uals will be plotted to check for normality and outliers.
Subgroup analyses
No subgroup analyses are planned. The study is not
powered to investigate interaction effects. In addition,
this analysis plan does not cover any further secondary
analyses of the trial dataset. Mediator and exploratory
moderator analyses may be performed after the primary
trial data analysis.
Software
Data management
An online data collection system for clinical trials
(MACRO) will be used. This is hosted on a dedicated
server at King’s College London and managed by the
KCTU.
Statistical analysis
Stata version 14.0 software (StataCorp, College Station,
TX, USA) will be used for data description and inferen-
tial analysis.
Economic analysis plan
Health economic objective and measures
We will take both a health/social care and a societal per-
spective in the assessment of cost-effectiveness. Societal
costs include lost employment and care from family/
friends. Permission to use Hospital Episode Statistics
data will be applied for to measure inpatient and other
hospital use; however, if this is not possible, then service
use will still be measured with the Client Service Receipt
Inventory [25] questionnaire, which is collected at
baseline and at 6- and 12-month follow-up, and this will
supplement information on number of therapy sessions
provided.
Costs will be calculated by combining the service use
data with recognised unit costs [26, 27]. Wage rates will
be used to value lost work and care from family/friends.
Intervention unit costs will be based on salaries,
overhead costs, training and supervision.
Costs will be compared between the two arms at
6- and 12-month follow-up (the latter being the cumula-
tive costs over the entire follow-up period). Baseline costs
will be controlled for in a bootstrapped regression model
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(given the likely skewed data distribution). We will report
95% CIs around the cost difference at each time point.
To assess cost-effectiveness, costs will be combined
with change in DS frequency and also quality-adjusted
life-years (QALYs) derived from the five-level European
Quality of Life-5 Dimensions (EQ-5D-5L) [28] using the
AUC approach. Incremental costs and outcomes will be
obtained via regression models, and 1000 differences
obtained from bootstrapped resamples will be plotted on
a cost-effectiveness plane to investigate uncertainty
around the incremental cost-effectiveness ratio obtained
from point estimates.
Sensitivity analyses will be conducted with missing
follow-up costs and QALYs derived via MI. If an individ-
ual has a missing number of service contacts or a miss-
ing EQ-5D domain score, then the median of others
with these data will be used. Other sensitivity analyses
will use QALYs derived via the SF-6D, derived from the
12-item Medical Outcomes Study Short Form Health
Survey version 2.0 (SF-12v2) [29, 30]. Furthermore, we
will use home care workers as alternative values for
informal care. There has been limited previous
research in this area, and this trial will provide evi-
dence on the impact of CBT in patients with DS over
a 1-year follow-up.
Trial status
Recruitment completed on May 31st 2017 and the trial
is now in final follow-up stages.
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